Adrenomedullin levels in patients with Familial Mediterranean Fever: a long term follow-up

Polat, Adem; Sağlam, Celal; Kurt, Yasemin Gülcan; Basbozkurt, Gokalp; Sözeri, Betül; Dursun, İsmail; Kasapçopur, Özgür; Peru, Harun; Şimşek, Doğan; Gündüz, Zübeyde; Ünsal, Erbil; Gök, Faysal; Özen, Seza; Demirkaya, Erkan

doi:10.1186/1546-0096-12-s1-p242

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in order to investigate the subclinical inflammation present between FMF attacks, Polat et al conducted a clinical trial with FMF patients at different colchicine dosages. No changes in ADM were demonstrated, suggesting the continuation of the clinical inflammatory process in these patients [ 76 ].…”

Section: Resultsmentioning

confidence: 99%

“…This peptide seems to have a role in all these pathologies, and in the case of VUR, it seems to identify patients with parenchymal scarring. ADM may have a role in the immune-inflammatory process of HSP, ARF, and FMF, although how they affect inflammatory injury is not clear [ 73 , 75 , 76 ]. In KD, this biomarker may be useful to monitor patients during its acute phase and may help to determine coronary artery involvement [ 72 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Adrenomedullin in Pediatric Patients: A Useful Biomarker

2022

View full text Add to dashboard Cite

Adrenomedullin has several properties. It acts as a potent vasodilator, has natriuretic effects, and reduces endothelial permeability. It also plays a role in initiating the early hyperdynamic phase of sepsis. Since its discovery, many articles have been published studying the uses and benefits of this biomarker. The aim of this review is to determine the usefulness of adrenomedullin in pediatric patients. Relevant studies covering adrenomedullin in pediatrics (<18 years) and published up until August 2021 were identified through a search of MEDLINE, PubMed, Embase, Web of Science, Scopus, and Cochrane. Seventy studies were included in the present review, most of them with a low level of evidence (IV to VI). Research on adrenomedullin has primarily been related to infection and the cardiovascular field. The performance of adrenomedullin to quantify infection in children seems satisfactory, especially in sepsis. In congenital heart disease, this biomarker seems to be a useful indicator before, during, and after cardiopulmonary bypass. Adrenomedullin seems to be useful in the pediatric population for a large variety of pathologies, especially regarding infection and cardiovascular conditions. However, it should be used in combination with other biomarkers and clinical or analytical variables, rather than as a single tool.

show abstract

Section: Resultsmentioning

confidence: 99%